Literature DB >> 8536643

Corticotropin-releasing factor (CRF) and glucocorticoids modulate the expression of type 1 CRF receptor messenger ribonucleic acid in rat anterior pituitary cell cultures.

G Pozzoli1, L M Bilezikjian, M H Perrin, A L Blount, W W Vale.   

Abstract

Previous studies involving radioreceptor and functional assays have shown that CRF and glucocorticoids are able to modulate CRF receptors of the brain and anterior pituitary. In this study, we analyzed the effects of CRF, vasopressin (AVP), dexamethasone (DEX), and corticosterone on the regulation of CRF receptor (CRF-R1) messenger RNA (mRNA) levels in cultured rat anterior pituitary cells. CRF decreased CRF-R1 mRNA levels in a time- and concentration-dependent manner. In the presence of 10 nM CRF, CRF-R1 mRNA levels decreased within 1 h (to 65 +/- 3% of the control value; P < 0.01) with a maximal effect after 3 h (to 28 +/- 1% of the control value; P < 0.001). The concentration dependence of the inhibitory effect of CRF at 3 h correlated with that required for ACTH secretion (half-maximal at approximately 0.03 nM). Treatment with a maximal (100 nM) dose of AVP or a submaximal (0.1 nM) dose of CRF for 3 h reduced CRF-R1 mRNA levels to 66 +/- 3% and 53 +/- 6% of the control value, respectively. In the presence of both AVP and CRF, CRF-R1 mRNA levels were 32 +/- 3% of the control value. The incubation of cells for 3 h with 10 microM forskolin to activate adenylate cyclase or with 20 nM 12-0-tetradecanoylphorbol-13-acetate to activate protein kinase C resulted in a decrease in receptor mRNA levels to 40 +/- 9% (P < 0.01) and 28 +/- 8% (P < 0.001) of the control value, respectively, suggesting that the effects of CRF and AVP may be mediated by these pathways. DEX (20 nM) also caused a dose- and time-dependent decrease in mRNA levels. Maximal inhibition was observed after 3 h (to 31 +/- 6% of the control value; P < 0.001), with a partial recovery of mRNA levels at 24 or 48 h. Corticosterone similarly inhibited the accumulation of CRF-R1 mRNA in a dose- and time-dependent manner, but, in contrast to DEX, CRF-R1 mRNA levels returned almost to control levels after 24 h. These results indicate that the ability of CRF, AVP, and glucocorticoids to modulate the responses of corticotropes to CRF may be due in part to the actions of these agents on CRF-R1 mRNA accumulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8536643     DOI: 10.1210/endo.137.1.8536643

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  19 in total

1.  Impact of maternal undernutrition on hypothalamo-pituitary-adrenal axis and adipocyte functions in male rat offspring.

Authors:  A N Chisari; A Giovambattista; M Perello; E Spinedi
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 2.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

3.  Reduced activity of hypothalamic corticotropin-releasing hormone neurons in transgenic mice with impaired glucocorticoid receptor function.

Authors:  I Dijkstra; F J Tilders; G Aguilera; A Kiss; C Rabadan-Diehl; N Barden; S Karanth; F Holsboer; J M Reul
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

4.  Plasma leptin and ghrelin in the neonatal rat: interaction of dexamethasone and hypoxia.

Authors:  Eric D Bruder; Lauren Jacobson; Hershel Raff
Journal:  J Endocrinol       Date:  2005-06       Impact factor: 4.286

5.  Bacterial lipopolysaccharide-induced coordinate downregulation of arginine vasopressin receptor V3 and corticotropin-releasing factor receptor 1 messenger ribonucleic acids in the anterior pituitary of endotoxemic steers.

Authors:  Isam M Qahwash; Carolyn A Cassar; Roy P Radcliff; George W Smith
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

Review 6.  Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.

Authors:  H Lehnert; C Schulz; K Dieterich
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

7.  In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland.

Authors:  Enrique Sánchez-Lemus; Julius Benicky; Jaroslav Pavel; Juan M Saavedra
Journal:  Brain Behav Immun       Date:  2009-05-07       Impact factor: 7.217

Review 8.  Sex differences in stress-related psychiatric disorders: neurobiological perspectives.

Authors:  Debra A Bangasser; Rita J Valentino
Journal:  Front Neuroendocrinol       Date:  2014-04-12       Impact factor: 8.606

9.  Sequences, expression patterns and regulation of the corticotropin-releasing factor system in a teleost.

Authors:  Chun-Chun Chen; Russell D Fernald
Journal:  Gen Comp Endocrinol       Date:  2008-04-14       Impact factor: 2.822

10.  Regulation of corticotropin releasing hormone receptor (CRH-R) in the rat anterior pituitary as assessed by radioimmunoassay.

Authors:  Takeshi Nigawara; Nobuo Horiba; Fumiko Tozawa; Yoko Kasagi; Katsuya Uchida; Yasumasa Iwasaki; Toshihiro Suda
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.